Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMC 001 - Suzhou Immunofoco Biotechnology

Next Previous
X
Search
Drug Profile

IMC 001 - Suzhou Immunofoco Biotechnology

Alternative Names: EpCam CAR-T cell therapy - Suzhou Immunofoco Biotechnology; IMC-001 - Suzhou Immunofoco Biotechnology

Latest Information Update: 03 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Immunofoco Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Gastric cancer

Most Recent Events

  • 24 Jun 2024 IMC 001 - Suzhou Immunofoco Biotechnology is available for licensing as of 07 Jun 2024. https://www.immunofoco.com/index.php?s=partners&c=category&id=2#a1
  • 07 Jun 2024 Suzhou Immunofoco Biotechnology plans pivotal clinical trial in 2025 (Suzhou Immunofoco Biotechnolgy pipeline, June 2024)
  • 07 Jun 2024 Suzhou Immunofoco Biotechnology completes a clinical trial in Gastric cancer (Late-stage disease) in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top